9/23/2020 9:37:53 AM
Capricor To Present Novel Data From Phase II HOPE-2 Clinical Trial
4/3/2020 8:03:27 AM
Capricor Initiates Compassionate Use Program For Severe COVID-19 Patients Using CAP-1002
10/7/2019 6:41:27 AM
Capricor Presents Addl Positive Data From HOPE-2 Study Of CAP-1002 At World Muscle Society
7/15/2019 6:08:52 AM
Capricor Therapeutics Announces Positive Results From Interim Analysis In HOPE-2 Trial
1/22/2019 7:05:38 AM
Capricor Says FDA Provides Positive Feedback On Design For HOPE-2 Clinical Trial
11/12/2018 7:03:24 AM
Capricor To Meet With FDA Under RMAT Designation To Discuss HOPE-2 Clinical Trial
7/17/2018 7:03:56 AM
Capricor, USAISR Announce Collaboration To Investigate Exosome Platform To Treat Injured Troops
4/30/2018 7:13:02 AM
Capricor Begins HOPE-2 Clinical Trial At UC Davis Medical Center
4/19/2018 7:07:49 AM
Capricor Announces New Pre-Clinical Study Finds Repeat Doses Of CAP-1002 Lead To Enhanced Exercise Capacity In Mdx Mouse
3/14/2018 4:00:55 PM
Capricor Therapeutics Q4 EPS $0.42 Vs. Loss $0.21 Year Ago